Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12...4567891011121314...2425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    LETERMOVIR CYTOMEGALOVIRUS PROPHYLAXIS IMPACTS ON POLYCLONAL IMMUNO-RECONSTITUTION DYNAMICS IN HSCT RECIPIENTS (Room 141) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_887;    
    Conversely, letermovir administration was associated with a slight improvement of B-cell reconstitution.Interestingly, NK-cells are higher among letermovir recipients. In this regard, role of CMV DNAemia blips and tardive CMV reactivations require further investigations.In our cohort, we confirmed a significant reduction of clinically relevant CMV in letermovir-recipients, and a reduction of moderate-to-severe cGVHD.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. (Pubmed Central) -  Jan 25, 2023   
    De novo letermovir resistance is rare and can be successfully treated using other antivirals. Letermovir effectively prevents clinically significant CMV, however, subclinical CMV reactivation occurs frequently at our center.
  • ||||||||||  Review, Journal:  Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections. (Pubmed Central) -  Dec 23, 2022   
    Fortunately, novel drugs (e.g., letermovir and maribavir) with less toxicity and drug/cross-resistance have been approved and put on the market in recent years...In this review, we would explore the challenges, recent advances and perspectives in the treatment of HCMV infections. Furthermore, the suitable therapeutic strategies as well as the possibility for compassionate use would be evaluated.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients after Stem Cell Transplant (World Center Marriott Crystal NPQ; In-Person) -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1330;    
    P2
    Letermovir prophylaxis is effective with minimal myelosuppression and toxicity, however, by 24 weeks post-HCT, the rate of clinically significant viremia rebounds, likely due to delayed recovery of polyfunctional pp65 and IE-1 T-cell responses...CMV viremia requiring antivirals developed in three recipients. In summary, this novel approach represents a promising strategy to enhance immune transfer and reconstitution of CMV-specific T cells and to potentially spare the use of antiviral prophylaxis, which is known to impair and delay CMV-specific immunity and can result in late CMV reactivation.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Noxafil (posaconazole) / Merck (MSD), Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
    Insurance Barriers to High-Cost Anti-Infective Medications Post Allogeneic Hematopoietic Cell Transplant () -  Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_1106;    
    Methods Medical records of pts who received high-cost medications (azoles & letermovir [LTV]) during their first allo-HCT (1/1/21 – 5/1/22) were evaluated for insurance type, ancestry/ethnicity, and stem cell source...Results In the azole (n=181, voriconazole n=91, posaconazole n=44, isavuconazole n=46) and LTV (n=121) groups, the median age was 60 (range 22-81) and 57yrs (range 22-81), respectively, with 40% female overall...Neither insurance type nor transplant characteristics predicted the level of barrier, which suggests that all patients should be assessed for financial toxicity. PharmDs played an integral role in overcoming the insurance barriers for these high-cost medications, and work is ongoing to expand our understanding of the financial issues impacting our pts.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Ovastat (treosulfan) / Medac, Medexus, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Haploidentical Hematopoietic Stem Cell Transplant Plus Add-Back NK Cells in Pediatric High-Risk ALL () -  Nov 29, 2022 - Abstract #ASH2022ASH_7917;    
    Patients 1 and 2 received chemo-based conditioning regimens consisting of thyotepa, and fludarabine; In addition, patient1received treosulfan, and patient 2 received busulfan...All patients received rituximab and letermovirfor EBV and CMV prophylaxis, respectively, for all patients...Thus, infusion of mature donor NK cells may help to maintain control of MRD and virus reactivation through immunologic surveillance. Although our preliminary observations seem to be promising, this hypothesis should be confirmed in clinical trial of a larger number of patients.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience () -  Nov 29, 2022 - Abstract #ASH2022ASH_7846;    
    Our real-world experience is in line with the well-established contiguity and causal relation between CMV infection and GVHD, showing a reduction in CS-CMVi during the prophylaxis period with a corresponding reduction in acute and chronic GVHD. Our cohort is limited by its retrospective nature and a relatively small sample size.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date:  Letermovir Use in Heart Transplant Recipients (clinicaltrials.gov) -  Nov 16, 2022   
    P4,  N=35, Recruiting, 
    Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected. Active, not recruiting --> Recruiting | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Oct 2025
  • ||||||||||  Review, Journal:  Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection. (Pubmed Central) -  Nov 15, 2022   
    Adoptive immunotherapy, the transfer of viral specific T-cells (VSTs), offers a new approach in treatment of drug-resistant or refractory viral infections, with early clinical trials showing promise with respect to efficacy and safety. In this review, we will discuss some of the encouraging results and challenges of widespread adoption of VSTs in care of immunocompromised patients, with an emphasis on the clinical outcomes for treatment and prophylaxis of CMV infection among high-risk patient populations.